Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Revenues Down, Losses Narrowed During Q2

NEW YORK, July 30 (GenomeWeb News) - Ciphergen Biosystems yesterday reported sliding revenues and narrowed losses for the second quarter.


The company booked $10.8 million in revenues for the quarter, down from $14.3 million during the same quarter in 2003.


R&D costs decreased to $6 million, from $7 million during the same quarter last year.


The company's net loss amounted to $13.1 million, down from $15.6 million during the second quarter a year ago. Last year's net loss included a $7.3 million non-recurring litigation settlement.


As of June 30, Ciphergen had $29.8 million in cash, cash equivalents and investments in securities.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.